13,14-dihydroxy-15-ketoprostaglandin f2alpha profile

## 13,14-Dihydroxy-15-ketoprostaglandin F2α (13,14-DH-15-keto-PGF2α)

**What is it?**

13,14-Dihydroxy-15-ketoprostaglandin F2α (13,14-DH-15-keto-PGF2α) is a **metabolite** of prostaglandin F2α (PGF2α). PGF2α is a naturally occurring hormone-like substance involved in various physiological processes, including uterine contractions, inflammation, and vasoconstriction.

**Key Features:**

* **Structure:** It is a derivative of PGF2α with two hydroxyl groups at positions 13 and 14, and a keto group at position 15.
* **Production:** 13,14-DH-15-keto-PGF2α is produced by the enzymatic degradation of PGF2α, primarily through the actions of **15-hydroxyprostaglandin dehydrogenase** (15-PGDH).
* **Excretion:** It is excreted in the urine and serves as a **biomarker** for PGF2α levels in the body.

**Why is it important for research?**

13,14-DH-15-keto-PGF2α is important for research due to its role as a biomarker and its involvement in various physiological processes:

* **Biomarker for PGF2α:** Its presence in urine can be used to assess PGF2α production and metabolism, providing valuable information for research involving:
* **Reproductive health:** Studying menstrual cycles, pregnancy complications, and fertility issues.
* **Inflammation:** Examining inflammatory processes in various conditions.
* **Vasoconstriction:** Investigating the role of PGF2α in vascular function and disease.
* **Studying the 15-PGDH enzyme:** This enzyme is crucial in regulating PGF2α levels and its activity can be influenced by various factors. Studying 13,14-DH-15-keto-PGF2α levels can provide insights into 15-PGDH function in health and disease.
* **Drug development:** Understanding the role of PGF2α in different physiological processes can lead to the development of new drugs that target this pathway for therapeutic purposes.

**Overall, 13,14-DH-15-keto-PGF2α serves as a valuable tool in research by providing insights into the production, metabolism, and physiological significance of PGF2α.**

**Important Note:** The above information is for general knowledge and educational purposes only. It is not intended as medical advice.

13,14-dihydroxy-15-ketoprostaglandin F2alpha: RN given refers to (5Z,9alpha,11alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6439116
MeSH ID	M0146625

Synonym
13,14-dioh-15-keto-pgf2alpha
(z)-7-[(1r,2r,3r,5s)-2-(1,2-dihydroxy-3-oxooctyl)-3,5-dihydroxycyclopentyl]hept-5-enoic acid
prost-5-en-1-oic acid, 9,11,13,14-tetrahydroxy-15-oxo-, (5z,9alpha,11alpha)-
13,14-dihydroxy-15-ketoprostaglandin f2alpha
69536-60-3

Excerpt	Relevance	Reference
" Oxytocin binding was suppressed by progesterone at every dosage tested."	( Direct inhibitory effect of progesterone on oxytocin-induced secretion of prostaglandin F(2alpha) from bovine endometrial tissue. Bogacki, M; Kotwica, J; Rekawiecki, R; Silvia, WJ, 2002)	0.31

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (28.57)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	2 (28.57)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (14.29%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	3.35	1	1	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	3.35	1	1	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	2.01	1	0
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.01	1	0
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	2.01	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.42	2	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	4.78	7	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	1.97	1	0	prostaglandins Falpha	human metabolite; mouse metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	1.97	1	0	thromboxanes B	human metabolite; mouse metabolite

Condition	Relationship Strength	Studies	Trials
Coronary Artery Stenosis [description not available]	2.31	1	0
Arteriosclerosis, Coronary [description not available]	2.31	1	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	2.31	1	0
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	2.31	1	0
Coronary Stenosis Narrowing or constriction of a coronary artery.	2.31	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.44	2	0
Pyrexia [description not available]	2.01	1	0
Ovine Diseases [description not available]	2.01	1	0
Group A Strep Infection [description not available]	2.01	1	0
Abortion, Septic Any type of abortion, induced or spontaneous, that is associated with infection of the UTERUS and its appendages. It is characterized by FEVER, uterine tenderness, and foul discharge.	2.01	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	2.01	1	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	2.01	1	0
Asthma, Bronchial [description not available]	3.35	1	1
Premenstrual Tension A term used to describe the psychological aspects of PREMENSTRUAL SYNDROME, such as the indescribable tension, depression, hostility, and increased seizure activity in women with seizure disorder.	3.35	1	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	3.35	1	1
Premenstrual Syndrome A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.	3.35	1	1

13,14-dihydroxy-15-ketoprostaglandin f2alpha

Description

Cross-References

Synonyms (5)

Research Excerpts

Dosage Studied

Research

Studies (7)

Market Indicators

Research Demand Index: 11.94

Study Types